Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9
Sheer R, Schwab P, Essex MN, Cappelleri JC, Reiners A, Bobula J, Pasquale MK. Factors related to the use of topical vs. oral NSAIDs for sprains, strains, and contusions in a senior population: a retrospective analysis of administrative claims data. Drugs Aging. 2018 Oct;35(10):937-50. doi: 10.1007/s40266-018-0585-8
Singh M, Rebordosa C, Bernholz J, Sharma N. Epidemiology and genetics of cystic fibrosis in Asia: in preparation for the next-generation treatments. Respirology. 2015 Nov 6;20(8):1172-81. doi: 10.1111/resp.12656
Schwab P, Louder A, Li Y, Mallick R, Bays H. Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe. Drugs Aging. 2014 Sep;31(9):683-94. doi: 10.1007/s40266-014-0200-6
Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012 May 1;95(5):535-44.
Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012 Mar 1;95(3):263-73.
Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011 Nov;16(8):1235-40. doi: 10.1111/j.1440-1843.2011.02030.x
Lukert B, Satram-Hoang S, Wade S, Anthony MS, Gao G, Downs R. Physician differences in managing postmenopausal osteoporosis: results from the POSSIBLE US™ treatment registry study. Drugs Aging. 2011 Sep 1;28(9):713-27.